ABC | Volume 113, Nº3, Setembro 2019

Artigo de Revisão Calderaro et al. Hipertensão pulmonar na prática do cardiologista Arq Bras Cardiol. 2019; 113(3):419-428 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 45. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, et al. Clinicaleffectsofendothelinreceptorantagonismwithbosentaninpatientswith severechroniche artfailure:resultsofapilotstudy.JCardFail. 2005;11(1):12-20. 46. Vachiery JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. EurRespirJ.2018;51(2) .pii:1701886.doi :10.1183/13993003.01886-2017. 47. Hsu S, Tedford RJ.Will we be singing a different tune on combined post- and pre-capillary pulmonary hypertension? Eur Respir J. 2018;51(2). 48. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al. Sildenafila improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116(14):1555-62. 49. Jabbour A, Keogh A, Hayward C, Macdonald P. Chronic sildenafila lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Eur J Heart Fail. 2007;9(6-7):674-7. 50. BocchiEA,GuimaraesG,MocelinA,BacalF,BellottiG,Ramires JF.Sildenafila effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation. 2002;106(9):1097-103. 51. Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, et al. Sildenafila inHeart failure (SilHF). An investigator-initiatedmultinational randomized controlled clinical trial: rationale and design. Eur J Heart Fail. 2013;15(1):119-22. 52. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failurewith preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268-77. 53. Ghio S, Bonderman D, Felix SB, Ghofrani HA, Michelakis ED, Mitrovic V, et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. Eur J Heart Fail. 2012;14(8):946-53. 54. Seger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109-16. 55. Kovacs G, Agusti A, Barbera JA, Celli B, Criner G, Humbert M, et al. Pulmonary Vascular Involvement in COPD - Is There a Pulmonary Vascular Phenotype? Am J Respir Crit Care Med. 2018. 56. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, et al. Long-Term Outcome of Patients With Chronic Thromboembolic PulmonaryHypertension:ResultsFroman InternationalProspectiveRegistry. Circulation. 2016;133(9):859-71. 57. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279-313. 58. Ghofrani HA, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5(10):785-94. 59. Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J. 2014;43(5):1394-402. 60. Fernandes CJ, JardimC, Carvalho LA, Farias AQ, FilhoMT, Souza R. Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease. J Inherit Metab Dis. 2005;28(4):603-5. 428